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Abstract
Introduction: Side-branch intraductal papillary mucinous neoplasms (IPMN) of the pancreatic head/
uncinate are an increasingly common indication for pancreaticoduodenectomy (PD). However, enucle-
ation (EN) may be an alternative to PD in selected patients to improve outcomes and preserve pancreatic
parenchyma.
Aim: To determine peri-operative outcomes in patients with side-branch IPMN of the pancreatic head/
uncinate undergoing EN or PD compared with a cohort of patients with pancreatic adenocarcinoma (PA)
undergoing PD.
Methods: Retrospective review of a prospectively collected, combined, academic institutional series
from 2005 to 2008. Of 107 pancreatic head/uncinate IPMN, enucleation was performed in 7 (IPMN EN)
and PD was performed in 100 (IPMN PD) with 17 of these radiographically amenable to EN (IPMN PDen).
During the same time period, 281 patients underwent PD for PA (Control PD).
Results: Operative time was shorter (p < 0.05) and blood loss (p < 0.05) was less in the IPMN EN group
compared with all other groups. Peri-operative mortality and morbidity of all IPMN groups (IPMN EN,
IPMN PDen) were similar to the Control PD group. Overall pancreatic fistulae rate in the IPMN EN group
was higher than in the IPMN PDen and Control PD groups; however, the rate of grade C pancreatic fistulae
was the same in all groups.
Conclusions: Pancreaticoduodenectomy for side-branch IPMNs can be performed safely. Compared
with PD, enucleation for IPMN has less blood loss, shorter operative time and similar morbidity, mortality,
hospital length of stay (LOS) and readmission rate. Enucleation should be considered more frequently as
an option for patients with unifocal side-branch IPMN.
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Despite a decrease in reported mortality, pancreaticoduodenec-
tomy (PD) remains a complex procedure with a high morbidity
rate.1–5 Overwhelmingly, this morbidity is as a result of post-
operative pancreatic fistula (POPF). Soft textured pancreas, a
small pancreatic duct and a fatty pancreas have been identified as
strong predictive factors of pancreatic fistula after PD1,5,6 Although
the incidence of pancreatic adenocarcinoma has remained stable
over the past decade, the frequency with which pancreatic surgery
has been undertaken has increased.7 This change has been due, in
part, to the increase in detection of cystic tumours such as intra-
ductal papillary mucinous neoplasms (IPMN).8,9 Unfortunately,
IPMN have an increased rate of POPF. Thus, patients need to be
fully informed of possible post-operative complications for a pre-
malignant and often asymptomatic disease. Enucleation of islet
cell tumours located in the head/uncinate process has been shown
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to reduce post-operative morbidity as compared with PD.10
Therefore, we hypothesized that a similar outcome could be
achieved for IPMN. Thus, the aim of the present study was to
determine the post-operative course of enucleation vs. PD for
IPMN of the head/uncinate of the pancreas.
Methods
Study groups
Patients undergoing pancreatic resection between 1 January 2005
and 12 December 2008 were identified from institutional review
board approved prospective databases maintained at Indiana Uni-
versity Hospital (IN, USA) and Institut Paoli Calmettes (Marseille,
France). Patients undergoing surgery for IPMN of the pancreatic
head/uncinate were divided into those undergoing enucleation
(IPMN EN) or pancreaticoduodenectomy (IPMN PD). Patients
undergoing PD for pancreatic ductal adenocarcinoma during the
same period were identified as a control group (Control PD).
Thus, 107 patients underwent pancreatic surgery for IPMN of the
pancreatic head/ uncinate, seven underwent enucleation whereas
100 had PD. During the same period, 281 patients who underwent
PD for pancreatic adenocarcinoma without any pre-operative
treatment comprised the control group.
Enucleation group
All patients with suspected IPMN were staged by endoscopic
ultrasound (EUS), thin-section contrast-enhanced helical dual
phase computerized tomography scanning (CT scan) and/or pan-
creatic magnetic resonance imaging (MRI) (Fig. 1). Eligibility cri-
teria for enucleation were (a) absence of previous pancreatic head
surgery, (b) side branch IPMN of the head or uncinate process,
(c) absence of main pancreatic duct dilatation, (d) absence of
mural nodule or thickness of cyst wall, and (e) ability to preserve
the main pancreatic duct as assessed by intra-operative ultrasound
(IOU).
Thus, 24 patients were identified for possible enucleation. Ulti-
mately, the surgical procedure performed was decided according
to institutional and individual surgeon preference. Seventeen of
these patients underwent PD while seven side-branch IPMNs
were enucleated. After a generous Kocher manoeuvre, the entire
pancreatic head was exposed. Intra-operative ultrasound imaging
was routinely done to assess absence of (a) involvement of the
main pancreatic duct, (b) mural nodules and (c) additional
IPMNs. Pancreatic parenchyma was carefully opened with liga-
tion of any vessels using fine sutures or cautery. The side-branch
IPMN was entirely dissected; and when possible, the communi-
cant duct was identified and ligated (Fig. 2). Frozen section
examination was undertaken to be sure that no carcinoma in situ
or invasive cancer was present. Closure of the pancreatic
parenchyema was left to the discretion of the individual surgeon.
A Jackson–Pratt drain was routinely positioned close to the resec-
tion field. PD was performed as previously described.3
Outcomes
The variables evaluated included age, gender, operative duration
(min), blood loss (ml), IPMN size (cm) defined as maximum
diameter at pathological analysis, presence of invasion, POPF
according to the International Study Group on Pancreatic Fistula
(ISGPF),11 overall morbidity including post-operative bleeding
Figure 1 Magnetic resonance cholangiopancreatography (MRCP) of
a patient with intraductal papillary mucinous neoplasms (IPMN) of
the uncinate process eligible for enucleation. White arrow shows the
communicating duct
Figure 2 Intra-operative photograph showing enucleation of the
uncinate process with identification of the communicating duct
(white arrow). Haemostasis of pancreatic parenchyma was perform
with 6/0 Prolene
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and reoperation, mortality, hospital length of stay (LOS) (days)
and readmission rate.
Statistical analysis
Data analyses were carried out with GraphPad Prism (GraphPad
Software Inc., La Jolla, CA, USA) and Excel 2004 (Microsoft,
Seattle, WA, USA). Statistical associations between categorical
factors were assessed using Fisher’s exact test. Statistical signifi-
cance was set at a P-value < 0.05.
Results
IPMN patients
During the study period, 107 patients underwent pancreatic
surgery for IPMN of the pancreatic head/uncinate, while 281
patients underwent pancreaticoduodenectomy (PD) for pancre-
atic adenocarcinoma (Control PD). Using the pre-operative and
intra-operative assessment criteria, 24 of 107 patients (22%) with
IPMN met the criteria for enucleation (Table 1). However, only
seven underwent enucleation (IPMN EN) while 100 patients
underwent pancreaticoduodenectomy (IPMN PD). One patient
who initially underwent enucleation was converted to a PD
because of concerning findings on frozen section. This patient was
included in the IPMN PD group. The IPMN EN and IPMN PD
patients were similar with respect to age and presenting symp-
toms. Most presented with pain whereas pancreatitis, jaundice
and weight loss were less common. The IPMN EN and IPMN PD
cyst size was similar (2.4 vs. 2.2 cm). All seven of the IPMN EN
patients had side-branch cysts whereas 39% of the IPMN PD
patients had main duct involvement (P < 0.05). None of the seven
IPMN EN patients had invasive cancer while 20% of the IPMN
PD patients had an invasive IPMN (P < 0.05).
Operative outcomes
Operative time was shortest in the IPMN EN patients (185 min,
P < 0.05). Operative duration also was shorter in the IPMN PD
than in the Control PD patients (309 vs. 382 min, P = 0.03).
Median blood loss was lowest in the IPMN EN patients (125 ml, P
< 0.05). Median blood loss was lower in IPMN PD than in Control
PD patients (592 vs. 859 ml, P = 0.06).
Post-operative outcomes
Postoperative outcomes of IPMN EN, IPMN PD and Control PD
patients are presented in Table 2. No mortality was observed in the
107 IPMN patients whereas 5 of 281 Control PD patients (1.8%)
died post-operatively. Overall, morbidity was similar in IPMN EN
(43%), IPMN PD (36%) and Control PD (42%) patients.
However, post-operative pancreatic fistulae were more common
in IPMN EN (43%) and IPMN PD (25%) than in Control PD
(14.2%) patients (P < 0.05). On the other hand, non-fistula
complications were not seen in IPMN EN patients and were
less common in IPMN PD (10%) than in Control PD (27.7%)
patients (P < 0.05). No differences were observed in
reoperation rates, hospital LOS or 30-day readmission rates.
The post-operative outcomes of the seven IPMN EN and the 17
IPMN patients eligible for enucleation who underwent PD IPMN
PDen are presented in Table 3. No differences were observed in
mortality (0%), overall morbidity (43% vs. 35%), pancreatic
Table 1 Age, symptoms and pathological findings of IPMN patients
IPMN EN IPMN PD
n 7 100
Median age (range) 61 (35–81) 66 (38–87)
IPMN-related symptoms (%) 7 (100) 85 (85)
Pain (%) 5 (71) 64 (64)
Pancreatitis (%) 2 (29) 10 (10)
Jaundice (%) 0 (0) 5 (5)
Weight loss (%) 0 (0) 6 (6)
IPMN size (cm) (range) 2.4 (1.2–4.2) 2.2 (0.4–5.2)
Branch duct IPMN (%) 7 (100) 61 (61)a
Mixed duct IPMN (%) 0 (0) 29 (29)
Main duct IPMN (%) 0 (0) 10 (10)
Margin with invasive IPMN (%) 0 (0) 1 (1)
Margin with non invasive IPMN (%) 0 (0) 8 (8)
Invasive IPMN (%) 0 (0) 20 (20)a
aP < 0.05 vs. IPMN EN.
IPMN, intraductal papillary mucinous neoplasms.
Table 2 Post-operative outcomes of IPMN and control patients
IPMN EN IPMN PD Control PD
N 7 100 281
Mortality (%) 0 0 5 (1.8%)
Morbidity
POPF (%) 3 (43) 25 (25)a 40 (14.2%)
Grade A (%) 2 (29) 9 (9) 14 (5)
Grade B (%) 1 (14) 15 (15) 22 (7.8)
Grade C (%) 0 (0) 1 (1) 4 (1.4)
Bleeding (%) 0 (0) 2 (2) 5 (1.8)
Cardiovascular/pulmonary (%) 0 (0) 8 (8) 29 (10.3)
Gastric emptying (%) 0 (0) 6 (6) 22 (7.8)
Biliary leak (%) 0 (0) 3 (3) 6 (2.1)
Wound infection (%) 0 (0) 4 (4) 8 (2.8)
Fascia dehiscence (%) 0 (0) 2 (2) 15 (5.3)
Other (%) 0 (0) 6 (6) 10 (3.6)
Overall morbidity (%) 3 (43) 36 (36) 118 (42)
Morbidity without POPF (%) 0 (0) 11 (11)a 78 (27.7)
Reoperation 0 (0) 7 (7) 15 (5.3)
Length of stay
(median days) (range)
12 (11–27) 14 (5–60) 14 (6–66)
Readmission (%) 1 (14) 14 (14) 35 (12.5)
aP < 0.05 vs. Control PD.
POPF, post-operative pancreatic fistula.
128 HPB
HPB 2011, 13, 126–131 © 2011 International Hepato-Pancreato-Biliary Association
fistula (43% vs. 12%), reoperation rate (0% vs. 12%), hospital LOS
(12 days) or 30-day readmission rates (14% vs. 12%).
Discussion
Pancreatic surgery remains a challenge with significant short- and
long-term morbidity.1–5 The management of side-branch IPMN
continues to be controversial because many of the lesions are
small and benign.11–17 Enucleation is an uncommon operation
which has been applied to other benign cystic and neuroendocrine
tumours.4,7,18–20 The present study documents the enucleation of
seven side-branch IPMN of the head/uncinate of the pancreas and
compares outcomes of 100 patients with IPMN and 281 with
pancreatic cancers undergoing PD. Enucleation was associated
with less blood loss and shorter operative time. Overall mortality
and morbidity were similar among the three groups. However, the
only morbidity associated with enucleation was low grade pancre-
atic fistulae.
IPMN of the pancreas may involve the main pancreatic duct,
side branches or both. Because of the relatively increased risk of
invasive cancer, resection is generally recommended for patients
with main duct or mixed IPMN.11–17 Resection is also accepted for
side-branch IPMN associated with symptoms or mural nodules as
well as in those larger than 3 cm in diameter.11–17 However, the
management of smaller side-branch IPMN in the absence of
symptoms or mural nodules, especially in elderly and/or frail
patients, remains controversial. When these lesions are in the
head/uncinate of the pancreas, the decision to observe or operate
becomes even more difficult because of the increased risk of PD
compared with distal pancreatectomy or enucleation.4,7
In the present study, the pancreatic fistula rate was significantly
higher in patients undergoing PD for IPMN than for pancreatic
cancer (25 vs. 14%, P < 0.05). This observation is not surprising as
most patients with IPMN have a relatively normal, soft pancreas
whereas those with pancreatic cancer tend to have associated
chronic pancreatitis with a dilated pancreatic duct. On the other
hand, the non-fistula morbidity was significantly lower in the
IPMN patients compared with the pancreatic cancer patients
undergoing PD (11 vs. 28%, P < 0.05). This observation may be
because of pre-operative differences in jaundice, biliary sepsis
and/or nutrition.
The pancreatic fistula rate was highest in patients with side-
branch IPMN who underwent enucleation (43%). However, this
rate was not statistically significantly higher than in the patients
undergoing PD for IPMN (25%) or pancreatic cancer (14%)
because of the small number of patients undergoing enucleation.
In addition, the three pancreatic fistulae in the enucleation
patients included two Grade A, one Grade B and no Grade C
fistulae. In comparison, Grade B and C fistulae occurred in 64% of
the IPMN and 65% of the pancreatic cancer patients who devel-
oped pancreatic fistulae after PD. Again, this difference in Grade
B/C fistulae between enucleation and PD patients (14 vs. 65%) is
not statistically significant. However, the small number of patients
undergoing enucleation may be the explanation as other reports
suggest that Grade B and C fistulae are uncommon after
enucleation.10,18–20
Several authors have reported enucleation of mucinous cystic
neoplasms (MCN) and serous cystadenomas (SCA).18–20 In these
analyses the blood loss and operative times were shorter than
comparable patients who underwent pancreatic resection. This
finding was also observed in the current report. While the initial
manoeuvres of enucleation and PD are the same, both the resec-
tion and the reconstruction, or lack thereof, are simpler with
enucleation. This difference explains why the blood loss and
operative time is less with enucleation. Multiple strategies have
been employed to reduce the risk of pancreatic fistula after PD.21–29
In this regard, several technical aspects of enucleation are
important.
First, with respect to enucleation, identification of the commu-
nicating duct on a preoperative MRI scan can be very helpful.30,31
Second, determination of the relationship between the cyst and
the main pancreatic duct with IOU is key, both with respect to the
decision to perform enucleation and to prevent a Grade B/C pan-
creatic fistula. Third, operative identification and ligation of the
communicating duct is an additional factor in patients with side-
branch IPMN as opposed to MCN, SCA or neuroendocrine
tumours (NET). Fourth, closure of the residual cavity in the pan-
creas may be a factor in reducing the incidence of Grade A fistu-
lae.19 Finally, the use and management of drains in these patients
may be more important than previously recognized.32,33
Historically, when the mortality of pancreatic resection was
very high, enucleation was recommended for small neuroendo-
crine tumours.10,21,34 In recent years, however, the mortality of
Table 3 Post-operative outcomes of IPMN EN and IPMN PDen
patients
IPMN EN IPMN PDen P-value
N 7 17 –
Mortality 0 (0) 0 (0) NS
Morbidity
POPF (%) 3 (43) 2 (12) NS
Grade A (%) 2 (29) 0 (0) NS
Grade B (%) 1 (14) 2 (12) NS
Grade C (%) 0 (0) 0 (0) NS
Bleeding (%) 0 (0) 2 (12) NS
Cardiovascular/pulmonary (%) 0 (0) 1 (6) NS
Delayed gastric emptying (%) 0 (0) 1 (6) NS
Overall morbidity (%) 3 (43) 6 (35) NS
Reoperation (%) 0 (0) 2 (12) NS
Length of stay
(median days) (range)
12 (11–27) 12 (7–35) NS
Readmission (%) 1 (14) 2 (12) NS
POPF, post-operative pancreatic fistula.
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pancreatic resection has decreased to less than 3% at high-volume
centres.1–5 Nevertheless, the morbidity of PD remains quite high;
and therefore, enucleation of small NET of the head/uncinate may
again be the procedure of choice.10,35 In a recent four-institution
comparison, enucleation of 23 head/uncinate NETs was associated
with shorter operative times, less blood loss, fewer complications
and shorter hospital LOS.10 In addition, no local recurrences were
observed among 37 enucleated patients and long-term survival
was similar to pancreatic resection. In the current report of
enucleation for side-branch IPMN in seven patients many of these
same trends were observed despite the small number of patients.
Another potential advantage of enucleation over resection is
preservation of pancreatic parenchyema. Both exocrine and endo-
crine function are diminished by pancreatic resection.36,37 In com-
parison, enucleation preserves the entire pancreas. A limitation of
this analysis is that neither exocrine nor endocrine function was
analysed in the enucleation or resection patients. Another limita-
tion is the relatively short follow-up. However, while complete
follow-up is not available in the 100 IPMN patients undergoing
PD, no recurrence has occurred in the seven IPMN patients who
underwent enucleation. As mentioned above, the small number of
patients managed with enucleation is the most significant limita-
tion of this analysis.
Several conclusions can be drawn from this report. For patients
with IPMN of the pancreatic head/uncinate, both PD and enucle-
ation can be performed safely. Enucleation is associated with
improved operative outcomes. While the pancreatic fistula rate is
high after enucleation, the majority are Grade A fistulae with little
clinical significance. Although not confirmed by this analysis,
enucleation may be associated with other improved post-
operative outcomes such as reoperation, hospital LOS and read-
missions. For these reasons, enucleation should be considered
more often in patients with a side-branch IPMN in the head/
uncinate of the pancreas.
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